Detalhe da pesquisa
1.
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.
Mol Ther;
30(5): 1885-1896, 2022 05 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34687845
2.
Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy.
Pharmaceuticals (Basel);
16(5)2023 May 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37242495
3.
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.
Mol Ther Methods Clin Dev;
31: 101110, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37822719
4.
Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.
Nat Commun;
14(1): 3035, 2023 05 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37236967
5.
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.
Cancer Cell;
4(4): 263-75, 2003 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14585354
6.
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Front Immunol;
13: 1029269, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36405739
7.
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX.
Front Immunol;
13: 1050250, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36713447
8.
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection.
J Vis Exp;
(172)2021 06 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34152313